NDA 021068 · Esjay Pharma
Rocaltrol
Calcitriol · Oral · Vitamin D3 Analog
Last checked: Nov 20, 2026Latest source record: May 15, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Nov 20, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
162
20 Phase 3, 4 recruiting
FAERS reports
20,257
15,687 serious, 2,692 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 10, 2026.
INDICATIONS & USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ROCALTROL · CALCITRIOL 1MCG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Calcitriol" as an intervention, any sponsor and status, largest first.
- Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on HemodialysisPivotal-lookingTerminated
AbbottIndustry
NCT00062699 · 2,200 participants · Start Apr 2003
Drug: Zemplar (paricalcitol injection); Calcijex · For: End-Stage Kidney Disease
Sites: Tuscaloosa, Alabama; Inglewood, California; Los Angeles, California · 60 sites in all
- DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])Pivotal-lookingTerminated
NovaceaIndustry
NCT00273338 · 1,200 participants (planned) · Start Jan 2006
Drug: calcitriol; docetaxel · For: Prostate Cancer
Sites: Birmingham, Alabama; Muscle Shoals, Alabama; Anchorage, Alaska · 222 sites in all
- The Relationship Between VDR Gene Polymorphism and Children's Physical and Intellectual DevelopmentPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT03742310 · 500 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2021
Drug: Vitamin D · For: Development, Child
Sites: Xi'an, China
- Chemoprevention of Colorectal AdenomasPivotal-lookingTerminated
Colotech A/SIndustry
NCT00486512 · 350 participants · Start Jun 2007 · Primary completion Nov 2010
Drug: 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol); 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3) and 2 more · For: Adenomatous Polyps
Sites: Huntsville, Alabama; San Diego, California; Clearwater, Florida · 39 sites in all
- An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 DiabetesPivotal-lookingStatus unknown
Hamad Medical CorporationIndustry
NCT03216564 · 320 participants (planned) · Start May 10, 2017 · Primary completion May 10, 2019
Drug: Calcitriol · For: Diabetic Nephropathies
Sites: Doha, Qatar
- A Study on the Prevention and Treatment of GIOP With EldecalcitolPivotal-lookingStatus unknown
Chinese SLE Treatment And Research GroupAcademic, hospital or other
NCT06385093 · 314 participants (planned) · Start Jun 2024 · Primary completion Dec 2025
Drug: Eldecalcitol capsules; Alfacalcidol tablets and 1 more · For: Rheumatoid Arthritis; Osteoporosis; Osteopenia
Sites: Beijing, China · 7 sites in all
- Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01181531 · 312 participants · Start Oct 1, 2010 · Primary completion Jul 17, 2012
Drug: Traditional Vitamin D Therapy; Cinacalcet · For: Hyperparathyroidism, Secondary
- Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01313221 · 310 participants · Start Apr 2011 · Primary completion Dec 2012
Drug: etanercept; Topical agents · For: Psoriasis
Sites: Calgary, Canada; Surrey, Canada; Vancouver, Canada · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,470
- diarrhoea1,194
- off label use1,162
- chronic kidney disease1,115
- vomiting1,109
- dyspnoea1,099
- renal failure1,058
- fatigue1,050
- acute kidney injury973
- death908
- drug hypersensitivity882
- drug ineffective801
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 179 |
| 2005 | 245 |
| 2006 | 171 |
| 2007 | 190 |
| 2008 | 282 |
| 2009 | 388 |
| 2010 | 392 |
| 2011 | 400 |
| 2012 | 513 |
| 2013 | 525 |
| 2014 | 541 |
| 2015 | 863 |
| 2016 | 1,153 |
| 2017 | 1,378 |
| 2018 | 1,728 |
| 2019 | 2,327 |
| 2020 | 1,542 |
| 2021 | 1,449 |
| 2022 | 1,158 |
| 2023 | 1,212 |
| 2024 | 1,417 |
| 2025 | 1,212 |
| 2026 | 992 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rocaltrol (Calcitriol)
2024 spending
$17K
Beneficiaries
38
74 claims
Per beneficiary
$457
$12.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $43,677 |
| 2021 | $41,671 |
| 2022 | $46,389 |
| 2023 | $37,011 |
| 2024 | $17,347 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vitamin D supplementation in the critically ill: A systematic review and meta-analysis.
Langlois PL, Szwec C, D'Aragon F, et al. · Clin Nutr 2018 · Meta-Analysis, Systematic Review
- Effects of vitamin D supplementation on autoantibodies and thyroid function in patients with Hashimoto's thyroiditis: A systematic review and meta-analysis.
Tang J, Shan S, Li F, et al. · Medicine (Baltimore) 2023 · Meta-Analysis, Systematic Review
- Relationship between vitamin D levels and pediatric celiac disease: a systematic review and meta-analysis.
Sun Y, Zhou Q, Tian D, et al. · BMC Pediatr 2024 · Meta-Analysis, Systematic Review
- Effects of active vitamin D analogues on muscle strength and falls in elderly people: an updated meta-analysis.
Xiong A, Li H, Lin M, et al. · Front Endocrinol (Lausanne) 2024 · Meta-Analysis
- Effects of Vitamin D Supplementation on Renal Function, Inflammation and Glycemic Control in Patients with Diabetic Nephropathy: a Systematic Review and Meta-Analysis.
Wang Y, Yang S, Zhou Q, et al. · Kidney Blood Press Res 2019 · Meta-Analysis, Systematic Review
- Calcitriol in dialysis patients.
Maxwell DR, Benjamin DM, Donahay SL, et al. · Clin Pharmacol Ther 1978 · Clinical Trial, Comparative Study
Sponsor: Esjay Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.